Skip to content

Tianjin Inpatient Acute Myocardial Infarction Registry

Cohort Study of Acute Myocardial Infarction in Tianjin

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03600259
Acronym
TAMI
Enrollment
13000
Registered
2018-07-26
Start date
2018-01-01
Completion date
2023-12-01
Last updated
2022-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Acute

Keywords

Myocardial Infarction, Coronary Disease, Coronary Artery Disease, Myocardial Ischemia

Brief summary

Acute myocardial infarction(AMI) is the most serious manifestation of coronary artery disease. AMI is characterized by high mortality, high disability, and high cost. However, multicenter research on AMI with large sample size in Tianjin or even China is limited. By including AMI in 36 hospitals,this multicenter study will capture the changes in epidemiological trends ,analyze the status of treatment in Tianjin, and explore the best treatment strategies.

Interventions

None listed

Sponsors

Tianjin Chest Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Hospitalized patients with acute myocardial infarction according to Cardiac biomarker values \[Selective cardiac troponin (cTc) elevation and/or decline detection, at least one value exceeds the 99% reference limit (URL) and at least one of the following:(1)Symptoms of myocardial ischemia;(2)New or suspected new obvious ST-T changes or new left bundle branch block (LBBB);(3)ECG pathological Q waves;(4)Image evidence of recent loss of viable myocardium, or new regional wall motion abnormalities;(5)Coronary thrombosis confirmed by angiography or autopsy.\]

Exclusion criteria

* Those who did not meet the diagnosis of acute myocardial infarction (no myocardial ischemia-related symptoms, elevation of markers of myocardial necrosis and imaging findings of myocardial infarction); those who met the inclusion criteria but refused to participate in the study; The researchers judged that the subjects had poor compliance and could not Complete follow-up as required.

Design outcomes

Primary

MeasureTime frameDescription
Cardiac death1 yearDue to recent cardiac causes (eg myocardial infarction, low-volume heart failure, fatal arrhythmias), any deaths from unknown and unexplained deaths and all surgical-related deaths (including treatment-related deaths) will be attributed to cardiac death.Unless there is a clear non-cardiological cause, all deaths are considered heart disease. Specifically, even patients with concurrent potentially fatal non-cardiac diseases (such as cancer, infections) who have any accidental death should be classified as having a heart attack.

Secondary

MeasureTime frameDescription
Major adverse cardiovascular events10 days on average (during hospitalization)Composite of major adverse cardiovascular events (MACE) including cardiac death, heart failure, target vessel revascularization, recurrent myocardial infarction, stroke, severe bleeding

Countries

China

Contacts

Primary ContactYin Liu, M.D
tami2018@163.com+86-13502152283
Backup ContactJixiang Wang, PHD
tami2018@163.com+86-13752068790

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 27, 2026